TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27790824
Drug: G‐CSF with
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF with intracoronary (i.c.) injection of BMCs or serum (placebo)
Study: 27790824
Drug: G‐CSF with
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF with peripheral placebo (saline only)
Study: 21829466
Drug: 30 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 µg GMZ2
Study: 21829466
Drug: 100 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µg GMZ2
Study: 21829466
Drug: GMZ2 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMZ2 (both doses)
Study: 11339782
Drug: Diclofenac 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 100 mg suppository
Study: 7919313
Drug: Control (non-steroid)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (non-steroid)
Study: 3210286
Drug: Bland meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bland meal with 1950 mg of aspirin (positive control)
Study: 3210286
Drug: Spicy Mexican
Normalized name: Mexican tea pollen extract
DrugBank: Chenopodium ambrosioides pollen (DB10479)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spicy Mexican meal (30 g of jalapeño peppers)
Study: 868133
Drug: Isoniazid preventive
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid preventive treatment (300 mg daily for 24 weeks)
Study: 26382173
Drug: PTAS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTAS plus aggressive medical therapy
Study: 22367664
Drug: Methylphenidate delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate delivered through a long‐acting transdermal system (MTS) for 3 months
Study: 22367664
Drug: No-medication condition
Normalized name: salicylic acid Medicated Liquid Soap [No Zit Sherlock]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-medication condition for 3 months
Study: 19697299
Drug: Reminiscence therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reminiscence therapy (8 sessions over 2 months)
Study: 19697299
Drug: Comparison group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison group (no reminiscence therapy)
Study: 8106694
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (recombinant tissue‐type plasminogen activator, urokinase or combination therapy) with heparin, aspirin, and calcium‐channel blocking agent.
Study: 2520637
Drug: Histamine-receptor blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine-receptor blockade with 10 mg of chlorpheniramine and 400 mg of cimetidine intravenously before protamine infusion.
Study: 2520637
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no histamine-receptor blockade).
Study: 19381522
Drug: Inhaled milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled milrinone administered via jet nebulizer for 4 hours
Study: 19381522
Drug: Intravenous milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous milrinone (50 microg/kg bolus, then 0.5 microg/kg/min infusion for 4 hours)
Study: 10912546
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) therapy, 4 IU/m2 per day, for a maximum of 8 years
Study: 3555046
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin (750 mg twice daily)
Study: 3555046
Drug: Other antimicrobial
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antimicrobial therapy
Study: 29749371
Drug: Modafinil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (100 mg twice a day)
Study: 29749371
Drug: Intranasal mometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal mometasone furoate (100 µg in the evening)
Study: 27549387
Drug: Propofol-remifentanil anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol-remifentanil anesthesia with rocuronium 0.3 mg/kg
Study: 27549387
Drug: Propofol-remifentanil anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol-remifentanil anesthesia with rocuronium 0.6 mg/kg
Study: 27549387
Drug: Propofol-remifentanil anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol-remifentanil anesthesia with rocuronium 0.9 mg/kg
Study: 27549387
Drug: Sevoflurane-remifentanil anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane-remifentanil anesthesia with rocuronium 0.3 mg/kg
Study: 27549387
Drug: Sevoflurane-remifentanil anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane-remifentanil anesthesia with rocuronium 0.6 mg/kg
Study: 27549387
Drug: Sevoflurane-remifentanil anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane-remifentanil anesthesia with rocuronium 0.9 mg/kg
Study: 17920718
Drug: Interferon-alpha treatment
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha treatment for 52 weeks
Study: 16110408
Drug: Molecular targeted
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular targeted therapy (tyrosine kinase inhibitors, anti-sense oligonucleotides, angiogenesis inhibitors, endothelin receptor antagonists)
Study: 12409680
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors (SSRIs) (n=743)
Study: 10567778
Drug: gemifloxacin, 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemifloxacin, 320 mg p.o. once daily
Study: 44375
Drug: Sulpiride (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (400 ‐‐ 2100 mg/day)
Study: 28741675
Drug: Dinalbuphine sebacate
Normalized name: Dinalbuphine sebacate
DrugBank: Dinalbuphine sebacate (DB15341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinalbuphine sebacate (DNS) 150 mg
Study: 28741675
Drug: Nalbuphine HCl
Normalized name: nalbuphine HCl
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nalbuphine HCl 20 mg
Study: 23721547
Drug: Arbaclofen placarbil
Normalized name: Arbaclofen Placarbil
DrugBank: Arbaclofen Placarbil (DB08892)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arbaclofen placarbil (20 or 40 mg once daily, 20 or 30 mg twice daily)
Study: 23721547
Drug: Arbaclofen placarbil
Normalized name: Arbaclofen Placarbil
DrugBank: Arbaclofen Placarbil (DB08892)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arbaclofen placarbil (all doses)
Study: 19654232
Drug: Dialysate calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate calcium concentration (D(Ca)) of 1.00 mmol/L
Study: 19654232
Drug: Dialysate calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate calcium concentration (D(Ca)) of 1.50 mmol/L
Study: 19654232
Drug: Dialysate calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate calcium concentration (D(Ca)) of 1.25 mmol/L
Study: 15677600
Drug: Buprenorphine (12-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (12-16 mg)
Study: 15677600
Drug: Methadone (65-85
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (65-85 mg p.o.)
Study: 10592952
Drug: Syrup of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syrup of ipecac (SI) + home observation (HO)
Study: 8725983
Drug: Antibiotics for
Normalized name: ANTIBIOTICS FOR TOPICAL USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics for respiratory tract infections
Study: 27770561
Drug: elbasvir (EBR)
DrugBank: Elbasvir (DB11574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: elbasvir (EBR) 50 mg/grazoprevir (GZR) 100 mg with sofosbuvir (SOF) 400 mg for 4 weeks
Study: 27770561
Drug: elbasvir (EBR)
DrugBank: Elbasvir (DB11574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: elbasvir (EBR) 50 mg/grazoprevir (GZR) 100 mg with sofosbuvir (SOF) 400 mg for 6 weeks
Study: 27770561
Drug: elbasvir (EBR)
DrugBank: Elbasvir (DB11574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: elbasvir (EBR) 50 mg/grazoprevir (GZR) 100 mg with sofosbuvir (SOF) 400 mg for 8 weeks
Study: 27770561
Drug: elbasvir (EBR)
DrugBank: Elbasvir (DB11574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: elbasvir (EBR) 50 mg/grazoprevir (GZR) 100 mg with sofosbuvir (SOF) 400 mg for 12 weeks
Study: 27376706
Drug: Sofosbuvir 400
Normalized name: sofosbuvir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir 400 mg once daily plus ribavirin 1,000 mg/day for 16 weeks
Study: 27376706
Drug: Sofosbuvir 400
Normalized name: sofosbuvir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir 400 mg once daily plus ribavirin 1,000 mg/day for 24 weeks
Study: 27376706
Drug: Sofosbuvir 400
Normalized name: sofosbuvir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir 400 mg once daily plus ribavirin 1,200 mg/day for 16 weeks
Study: 27376706
Drug: Sofosbuvir 400
Normalized name: sofosbuvir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir 400 mg once daily plus ribavirin 1,200 mg/day for 24 weeks
Study: 22364892
Drug: onabotulinumtoxinA (botulinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: onabotulinumtoxinA (botulinum toxin injection to the glabellar region)
Study: 22364892
Drug: placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (saline injection)
Study: 19581770
Drug: Clevudine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clevudine therapy
Study: 17975845
Drug: Extracorporeal albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extracorporeal albumin dialysis (ECAD) + standard medical therapy (SMT)
Study: 16358599
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical anesthetic
Study: 12473473
Drug: Intranasal mupirocin
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal mupirocin ointment for 5 days
Study: 10496153
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil suspension (10mg/kg/day)
Study: 10496153
Drug: Cefaclor suspension
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor suspension (45mg/kg/day)
Study: 2696009
Drug: Dexamethasone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (4 mg before or after the operation or 8 mg after the operation)
Study: 2696009
Drug: 6-methylprednisolone (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-methylprednisolone (16 mg at the end of the operation)
Study: 326596
Drug: Mazindol therapy
Normalized name: Mazindol
DrugBank: Mazindol (DB00579)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mazindol therapy
Study: 28885054
Drug: Zephyr endobronchial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zephyr endobronchial valve (EBV) treatment
Study: 25204361
Drug: Topical minoxidil
Normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical minoxidil foam 5% (MTF)
Study: 23144466
Drug: DHEA (LiveWell,
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (LiveWell, 25 mg three times a day)
Study: 19394002
Drug: Acupuncture (according
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (according to traditional Chinese medicine principles)
Study: 17062435
Drug: High-dose omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose omega-3 (4.55 g omega-3/day)
Study: 17062435
Drug: Low-dose omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose omega-3 (1.95 g omega-3/day)
Study: 10965421
Drug: Tramadol hydrochloride
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol hydrochloride injection (Limadol), 100 mg
Study: 10965421
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available reference product, 100 mg
Study: 1352908
Drug: Ebrotidine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebrotidine (800 mg single oral dose)
Study: 1352908
Drug: Ebrotidine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebrotidine (3 days treatment)
Study: 1352908
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 days treatment)
Study: 6241188
Drug: 13-cis-retinoic acid
Normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 13-cis-retinoic acid (0.05 mg/kg)
Study: 6241188
Drug: 13-cis-retinoic acid
Normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 13-cis-retinoic acid (0.1 mg/kg)
Study: 6241188
Drug: 13-cis-retinoic acid
Normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 13-cis-retinoic acid (0.2 mg/kg)
Study: 6241188
Drug: 13-cis-retinoic acid
Normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 13-cis-retinoic acid (all doses)
Study: 29202566
Drug: Spray-Sol group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray-Sol group (18 patients) with HA nebulized using a new nasal device named Spray-Sol
Study: 29202566
Drug: Spray group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray group (15 patients) with HA nebulized with a common spray
Study: 29202566
Drug: Spray-Sol group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray-Sol group (18 patients)
Study: 25027139
Drug: Telecare management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telecare management (n=124) for 12 months with automated symptom monitoring and algorithm-guided stepped care approach to optimizing analgesics
Study: 22470117
Drug: INH-resistant cases
Approvals — FDA: no, EMA: no, PMDA: no
Description: INH-resistant cases during the continuation phase of treatment (after 3 months)
Study: 22470117
Drug: Drug-susceptible cases
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-susceptible cases infected with 'modern' Beijing lineage strains
Study: 11991558
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (FP) 88 microg twice daily
Study: 11991558
Drug: Oral zafirlukast
Normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral zafirlukast (Z) 20 mg twice daily
Study: 3615688
Drug: Imipramine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (mean dose = 233 mg/day)
Study: 29369537
Drug: Patiromer 16.8
Normalized name: patiromer 16.8 GM Powder for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patiromer 16.8 g/day (divided into two doses) with individualized titration
Study: 24279685
Drug: Control (Cyclosporin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Cyclosporin, mycophenolate and steroids)
Study: 24373555
Drug: Mixed tocotrienols
Normalized name: Mixed Tocotrienols 50mg Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed tocotrienols 200 mg twice daily
Study: 20360491
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection subcutaneous digital nerve block (SDNB)
Study: 20360491
Drug: Traditional (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional (two injection) digital nerve block (TDNB)
Study: 16491747
Drug: Medicine group
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicine group (Yiqi Jianpi Oral Liquid, twice each day, for 4 weeks)
Study: 12834665
Drug: Generic timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Generic timolol XE gel-forming solution
Study: 12834665
Drug: Pilopine gel
Normalized name: pilocarpine hydrochloride Ophthalmic Gel [Pilopine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilopine gel
Study: 9008994
Drug: Midlaser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midlaser therapy with TMJ/occlusal stabilization
Study: 28592888
Drug: GRAALL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GRAALL treatment
Study: 29106437
Drug: 120 units
Normalized name: cholecalciferol 120 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 units of abobotulinumtoxinA injected in 5 equal aliquots (24 units each) into 5 injection sites in the glabellar complex
Study: 20553679
Drug: Low-dose leuprolide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose leuprolide acetate administered subcutaneously at 4- to 5-day intervals up to 1 year
Study: 20553679
Drug: Single GnRH-agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single GnRH-agonist injection
Study: 20553679
Drug: Repeated dosing
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated dosing of GnRH-agonist
Study: 18295023
Drug: Early combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early combined immunosuppression (infliximab 5 mg/kg at weeks 0, 2, and 6, plus azathioprine)
Study: 26671202
Drug: Automated fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated fractional skin microneedling (0.5 mm depth) followed by application of topical anesthetic cream (Lidocaine 2.5% + Prilocaine 2.5%)
Study: 18061271
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia alone
Study: 20346190
Drug: Fibre-supplemented diet
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibre-supplemented diet (14 g/l)
Study: 15213095
Drug: ICE consolidation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICE consolidation therapy (idarubicin 9 mg/m2 x 3; cytarabine 3 g/m2 twice a day on days 1, 3, 5, 7; etoposide 75 mg/m2 x 7)
Study: 15213095
Drug: IcE consolidation
Approvals — FDA: no, EMA: no, PMDA: no
Description: IcE consolidation therapy (cytarabine 100 mg/m2 daily x 5, idarubicin x 2, etoposide x 5)
Study: 1827621
Drug: Methylprednisolone (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (0.6 mg/kg total body weight)
Study: 6119098
Drug: Quazepam 7.5
Normalized name: quazepam 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quazepam 7.5 mg
Study: 6119098
Drug: Quazepam 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quazepam 45 mg
Study: 6119098
Drug: Quazepam 0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quazepam 0 mg (placebo)
Study: 31004339
Drug: Autologous muscle-derived
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous muscle-derived cell (MDC) injection
Study: 26113648
Drug: 14 g
Normalized name: GINGER 14 g in 100 TOPICAL PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 g of free essential amino acids (EAA) with high leucine levels
Study: 23261050
Drug: Self-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of intranasal live attenuated influenza vaccine (SA-LAIV)
Study: 23261050
Drug: Health care
Normalized name: Health Care Lancing Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health care provider administration of intranasal live attenuated influenza vaccine (HCP-LAIV)
Study: 18802735
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no neoadjuvant therapy)
Study: 14646682
Drug: Comparison among
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison among treatment groups
Study: 1280910
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for lateral epicondylitis
Study: 30151895
Drug: 0.4 ml
Normalized name: ethanol 0.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 ml of daily olive oil supplementation per rooster (Group 3)
Study: 30151895
Drug: 0.2 ml
Normalized name: isopropyl alcohol 0.2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 ml of daily olive oil supplementation per rooster (Group 2)
Study: 24739333
Drug: Ghrelin (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ghrelin (5.0 μg/kg)
Study: 10616997
Drug: Trimetazidine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (60 mg orally per day, started 3 weeks preoperatively)
Study: 7488409
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 1000 mg daily
Study: 7488409
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 500 mg daily
Study: 2301519
Drug: Mifepristone (RU‐486)
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mifepristone (RU‐486) 50 mg
Study: 2301519
Drug: Mifepristone (RU‐486)
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mifepristone (RU‐486) 100 mg
Study: 2301519
Drug: Mifepristone (RU‐486)
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mifepristone (RU‐486) 200 mg
Study: 2301519
Drug: Mifepristone (RU‐486)
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mifepristone (RU‐486) 400 mg
Study: 2301519
Drug: Mifepristone (RU‐486)
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mifepristone (RU‐486) 600 mg
Study: 2301519
Drug: Mifepristone (RU‐486)
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mifepristone (RU‐486) 0 mg
Study: 31365099
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (30 μg/d)
Study: 25877442
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Lidose hard capsule
Study: 25877442
Drug: 145 mg
Normalized name: levodopa 145 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 145 mg nanoparticle tablet
Study: 17223857
Drug: Brivaracetam (10-1400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam (10-1400 mg)
Study: 17223857
Drug: Brivaracetam (1400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam (1400 mg)
Study: 17223857
Drug: Brivaracetam (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam (150 mg)